Announcing Investment from Human Longevity, Inc.

Edifice Health has developed the first biomarker composite scoring system to measure inflammatory and immune health. With the recent investment from Human Longevity, Inc.’s (HLI) corporate venture arm called Human Longevity and Performance Impact Venture Fund, the company launches with Series A financing and a model that tackles chronic inflammation.

2020-09-22T14:07:45-07:00September 22nd, 2020|News|
Go to Top